Helpline 07939 046 030
Freephone 0300 102 17 22*

What Is Neurofibromatosis?

10 May 2026

Nerve Tumours UK have again joined forces with RBH Creative Communications, for a fifth successive year, to raise awareness of Neurofibromatosis via a new digital media campaign.

"In planning this year's digital campaign, we asked ourselves what, most of all, we wanted to achieve. The answer was simple and obvious. We need more people to know what Neurofibromatosis is and to know how to find our help. That led us to a simple campaign concept, asking the straightforward question 'What Is Neurofibromatosis?' Most people will not know the answer!

"But what do we all do nowadays, when we do not know the answer? We look it up! It is only by increasing the wider public perception and appreciation of NF, and raising its profile, that we can hope for continued and increasing support for the NF Community.

"Over recent years, we have been really fortunate to work with the creative team at RBH and their generous support of our work helps unlock this kind of large-scale awareness drive. RBH's passion for what we do, along with their collaborative approach, helps us to highlight NF more widely, showcasing our support services for those with the condition.

"I'm always delighted to hear the warm, positive response to the campaigns, both from the NF Community and those finding us for the first time as they pass through UK rail hubs or see our adverts elsewhere, so I am very much looking forward to seeing what comes of this year's campaign!" Karen Cockburn, Charity Director

What Is Neurofibromatosis?

Neurofibromatosis is an incurable, neuro-genetic condition that causes tumours to grow on nerve endings, affecting over 26,500+ children and adults living in the UK.

Neurofibromatosis, collectively known as NF, is the medical group name for Neurofibromatosis Type 1 (NF1), NF2-related-Schwannomatosis (NF2) and Schwannomatosis (SWN).

Combined, NF is one of the most common neuro-genetic conditions, although it can still be classified as a rare condition. NF manifests itself differently from person to person and so it is important that everyone is helped on an individual basis. Parents have a 50% chance of passing this genetic condition onto their child, but 50% of all diagnoses are a first one within the family.

Working For The NF Community

For over 45 yearsNerve Tumours UK has provided support and advice to help the 26,500+ children and adults in the UK diagnosed with NF, along with their carers, family members and wider support network, which can include teachers, employers and all types of healthcare professionals.

We do this through funding a unique specialist support network, comprising regional nursesnational helpline, clinical guidelines, information days, an interactive website, online communities plus medical guidelines/literature.

Support Our Work

Our aim is to meet the needs of the 26,500+ in the NF Community, to ensure that each and every patient has direct access to the correct care path and subsequent services, as well as helping more people to know about and better understand Neurofibromatosis. We are 100% funded by voluntary donations, so are entirely reliant on your fundraising support.

"Walking through UK Rail Hubs and the London Underground, you might encounter striking new digital billboards that pose the simple but vital question: "What is Neurofibromatosis?" This bold campaign for Nerve Tumours UK aims to combat the lack of awareness surrounding a condition that affects over 26,500+ people in the UK.

"The visual heart of the campaign is an illustration of the human nervous system. To represent the often-invisible reality of chronic pain associated with the condition, the artwork features a ‘glowing’ animation that pulses at the nerve endings. The intention of this glow is to spark curiosity and empathy in passers-by.

"By highlighting the physical complexity of the condition, the campaign motivates the public to look beyond the long name and discover the human stories behind it.

"We at RBH are immensely proud to have partnered again with Nerve Tumours UK on this project. Shedding light on such an important cause through creative storytelling is at the core of what we do, and we’re thrilled to help amplify their voice." RBH Creative Communications

The campaign will run across 27 rail hubs from 16-23 May 2025, covering both World NF Awareness Days on May 17 (NF1) and May 22 (NF2) respectively.

#MakeNFVisible

Billboard location map

Click this link for the exact locations of our digital poster campaign.

NTUK Rail Hub Locations

The campaign features on billboards at these railway stations: Birmingham New Street Station, Brighton Station, Bristol Temple Meads Station, Cambridge Station, Edinburgh Waverley Station, Liverpool Lime Street Station, London Blackfriars Station, London Bridge Station, London Charing Cross Station, London City Thameslink Station, London Elephant And Castle Station, London Euston Station, London Kings Cross Station, London Stansted Airport Station, London St Pancras Station, London Waterloo Station, Manchester Piccadilly Station, Nottingham Station, Oxford Parkway Station, Sheffield Station

Share our awareness campaign on your social media or take a photo on location.
Tag @nervetumoursuk with #MakeNFVisible in your posts

World NF Month 2026 'What Is Neurofibromatosis?' Campaign
 

Edinburgh Waverley Station

Clemence (left) and Sarah (right)

London Blackfriars Station

London Bridge Station

London Charing Cross Station

London Euston Station

London Kings Cross Station

London St Pancras Station

London Waterloo Station

If you or anyone you know is affected by NF, then please get in touch.

Our National Helpline is open on Monday, Wednesday & Friday 9am-5pm Call 07939 046 030, Freephone 0300 102 17 22 or Email helpline@nervetumours.org.uk

On Tuesday or Thursday, you can speak with the Head Office team, between 9am-5pm on 020 8439 1234, and they can book you a callback appointment with one of our Specialist NF Nurses.

Outside of these hours, and if you think it is an emergency, please don't hesitate to contact your GP or go to your nearest A&E Department for immediate professional support.

For further information on anything to do with NF, please visit our Help Section.

Masterclasses in NF: Ophthalmologic Findings & Orthopic Eye Examination in NF1 and NF2-Related Schwannomatosis

Ophthalmologic Findings & Orthopic Eye Examination in NF1 and NF2-Related Schwannomatosis

Prof. Dr. Berthold Pemp

OT Sabine Koinig

Masterclasses in NF: Plexiform Neurofibromas in NF1 - General Course and Neuroradiology

Plexiform Neurofibromas in NF1 - General Course and Neuroradiology

Assoc. Prof. Dr. Gregor Kasprian

Dr. Hector Salvador, MD

Masterclasses in NF: The Patients’ Perspective: A Masterclass on NF Care Held by NF Patients

Masterclasses in NF: Treatment Strategies for Vestibular Schwannomas: When to Treat? How to Treat?

Treatment Strategies for Vestibular Schwannomas: When to Treat? How to Treat?

 

Michel Kalamarides MD

Masterclasses in NF: Management Of Plexiform Neurofibromatosis in NF1- Rianne Oosterbrink, Justus L Groen, Karine Lascelles

Masterclasses in NF1: 1.Management Of Plexiform Neurofibromatosis in NF1

Rianne Oosterbrink MD

Justus L Groen MD

Karine Lascelles MD

Masterclasses in NF: Constitutional Mismatch Repair Deficiency Syndrome as Differential Diagnosis to NF1/Legius Syndrome - Prof. Dr. Katharina Wimmer

Constitutional Mismatch Repair Deficiency Syndrome as Differential Diagnosis to NF1/Legius Syndrome

Prof. Dr. Katharina Wimmer, Medical University of Innsbruck

Masterclasses in NF: Rare NF1-Associated Tumors in Adults - Eric Legius & Prof. Ellen Denayer

Masterclasses in NF: Rare NF1-Associated Tumors in Adults

Eric Legius, MD, PhD, University Hospital Leuven

Prof. Ellen Denayer, University Hospital Leuven

Masterclasses in NF: Optimising Hearing Outcomes in NF2-Related Schwannomatosis - Simon Freeman

Masterclasses in NF: Optimising Hearing Outcomes in NF2-Related Schwannomatosis

Simon Freeman, MPhil FRCS, Manchester Royal Infirmary and Salford Royal Hospital

Masterclasses in NF: NF1 Dermatological Manifestations - Pierre Wolkenstein, Laura Fertitta & Sirkku Peltonen

Masterclasses in NF: NF1 Dermatological Manifestations

Pierre Wolkenstein, MD, PhD, Hopital Henri-Mondor, Paris, France

Laura Fertitta, MD, Hôpital Universitaire Henri Mondor

Sirkku Peltonen, MD, PhD, University of Gothenberg, Sweden

Masterclasses in NF: Breast Cancer in NF1 - Gareth Evans

Masterclasses in NF: Breast Cancer in NF1

Gareth Evans, MD, University of Manchester, UK

Masterclasses in NF: Pain in Non-NF2-Related Schwannomatosis - David Pang

Masterclasses in NF: Pain in Non-NF2-Related Schwannomatosis

David Pang, MD, ChB. Guys and St Thomas' Hospital NHS Trust, London

Masterclasses in NF: Distinguishing Non-NF2-Related from NF2-Related Schwannomatosis - Clinical and Genetic Approaches - Said Farschtschi

Masterclasses in NF: Distinguishing Non-NF2-Related from NF2-Related Schwannomatosis - Clinical and Genetic Approaches

Said Farschtschi, MD, University Medical Center, Hamburg-Eppendorf, Germany

Masterclasses in NF: NF1 Pre-Implantation Genetic Diagnosis - Eric Legius & Prof. Ellen Denayer

Masterclasses in NF: NF1 Pre-Implantation Genetic Diagnosis

Eric Legius, MD, PHD, University Hospital of Leuven, Belgium

Prof. Ellen Denayer, University Hospital of Leuven, Belgium

NF2 Working Together: from a tentative diagnosis and beyond

Understanding the impact that a tentative diagnosis has on a parent. Information and access to the existing NTUK and Specialist Nerve Tumours medical and non medical care network.

NF1 Working Together Part 2: from a tentative diagnosis and beyond

Understanding the impact that a tentative diagnosis has on a parent. Information and access to the existing NTUK and Specialist Nerve Tumours medical and non medical care network.

NF1 Working Together Part 1: from a tentative diagnosis and beyond

Understanding  the impact that a tentative diagnosis has on a parent. Information and access to the existing NTUK and Specialist Nerve Tumours medical and non medical care network.

Masterclasses in NF: Surgery in NF2 - Michel Kalamarides & Andrew King

Masterclasses in NF: Surgery in NF2

Michel Kalamarides, MD, PhD, Hôpital Pitié-Salpêtrière, Paris, France

Prof Andrew King, MBBS FRCS FRCS(SN), Salford Royal Hospital, Manchester, United Kingdom. Member of the MAB of Nerve Tumours UK

Masterclasses in NF: Cognition and Behaviour in NF1: Phenotype and Treatment Approaches - Shruti Garg, Andre Rietman

Masterclasses in NF: Cognition and Behaviour in NF1: Phenotype and Treatment Approaches

Dr Shruti Garg, MBBS, MRCPsych, MMedSci, PhD, Royal Manchester Children’s Hospital, United Kingdom. Member of the MAB of Nerve Tumours UK

Andre Rietman, PhD, Erasmus University Medical Center, Rotterdam, Netherlands

Masterclasses in NF: Emotional Challenges in NF1, NF2 and Schwannomatosis - Susie Henley, Thomas Pletschko & Verena Rosenmayr

Masterclasses in NF: Emotional Challenges in NF1, NF2 and Schwannomatosis

Susie Henley, DClinPsy, PhD, Guy’s and St Thomas’ NHS Foundation Trust, London UK

Thomas Pletschko, PhD, Medical University of Vienna, Austria

Verena Rosenmayr, Clinical Psychologist, Medical University of Vienna, Austria

Masterclasses in NF: NF1 Pediatric Management - Rianne Oostenbrink

Masterclasses in NF: NF1 Pediatric Management

Rianne Oostenbrink, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands

Masterclasses in NF: Associated Glioma in Children - the Optic Pathway and Beyond - Amedeo Azizi

Masterclasses in NF: Associated Glioma in Children - the Optic Pathway and Beyond

Amedeo Azizi, MD, PhD, Head of the Paediatric Neurofibromatosis Program and Paediatric Neuro-Oncology Program, Medical University of Vienna, Austria

Masterclasses in NF: NF1 Orthopedic Manifestations - Eric Legius and Christophe Glorion

Masterclasses in NF: NF1 Orthopedic Manifestations

Eric Legius, MD, PhD. Head of Clinical Genetics Department of the University Hospital Leuven, Belgium

Christophe Glorion, MD, PhD, Department of Paediatric Orthopedic and Traumatologic Surgery, Hopital Necker-Enfants Malades, Paris, France. 

Masterclasses in NF: NF1 Malignant Peripheral Nerve Sheath Tumours - Rosalie Ferner and Viktor-Felix Mautner

Masterclasses in NF: NF1 Malignant Peripheral Nerve Sheath Tumours

Prof Rosalie Ferner, Consultant Neurologist and Lead Clinician for Neurofibromatosis, Guy's and St. Thomas' NHS Foundation Trust, London. Member of the MAB of Nerve Tumours UK and Trustee of Nerve Tumours UK

Viktor-Felix Mautner, MD, PhD. University Medical Centre in Hamburg-Eppendorf, Germany. Head of NF Outpatient Department

Masterclasses in NF - Neurofibromatosis Type 1: Cutaneous Neurofibromas - Pierre Wolkenstein and Sirkku Peltonen

Masterclasses in NF - Neurofibromatosis Type 1: Cutaneous Neurofibromas

Pierre Wolkenstein, MD, PhD. Hopital Henri-Mondor, Paris, France. Head of the Department of Dermatology

Sirkku Peltonen MD, PhD. University of Gothenberg, Sweden. Professor of Dermatology

INFER (International NF Educational Resources) is a series of online educational lectures for medical professionals by leading neurofibromatosis experts. The Masterclasses take place online approximately once a month, each on a different topic, and include real-time interaction between the expert presenter and the participants. The presentations are conducted in English, with real-time audio interpretation available in 6 additional languages: French, German, Italian, Portuguese, Russian, and Spanish. A recording of each INFER masterclass is then be made available online in each language for those who could not attend an event. INFER is an initiative of Children’s Tumor Foundation Europe, supported by an educational grant from AstraZeneca. https://ctfeurope.org/research/masterclasses-in-nf

BPNA Keynote Lecture - Prof Rosalie Ferner - Neurofibromatosis 1 in the 21st Century

‘Neurofibromatosis 1 in the 21st Century’

Keynote Lecture at the 48th British Paediatric Neurology Association Annual Scientific Meeting on 21st January 2022

Prof Rosalie Ferner, Consultant Neurologist and Lead Clinician for Neurofibromatosis, Guy's and St. Thomas' NHS Foundation Trust, London. Member of the MAB of Nerve Tumours UK and Trustee of Nerve Tumours UK